دورية أكاديمية
Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies.
| العنوان: | Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies. |
|---|---|
| المؤلفون: | Van Pesch, Vincent, Sindic, Christian, Fernández, Oscar |
| المساهمون: | UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie |
| المصدر: | Clinical Neurology and Neurosurgery, Vol. 149, p. 55-63 (2016) |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2016 |
| المجموعة: | DIAL@UCL (Université catholique de Louvain) |
| مصطلحات موضوعية: | Effectiveness, Multiple sclerosis, Natalizumab, Observational study, Real-world, Safety |
| الوصف: | Clinical trials have shown that natalizumab is highly effective for treating relapsing forms of multiple sclerosis (MS). The purpose of this analysis was to conduct a targeted review of data from country-specific observational studies and registries of natalizumab-treated patients with relapsing MS in order to more fully investigate the longer-term effectiveness and safety of this disease-modifying therapy in real-world clinical practice settings. A PubMed search was conducted on March 13, 2014, using the terms (natalizumab AND multiple sclerosis) AND (observational OR registry OR post-marketing OR clinical practice). Only English-language papers that reported effectiveness (in terms of effects on relapses, disability progression, and magnetic resonance imaging findings) and/or safety results from studies were included. Data from 22 studies/registries were included. Annualized relapse rates decreased by 73%-94% from baseline across the studies, with improvement maintained for up to 5 years during natalizumab treatment. Natalizumab effectiveness was also demonstrated via assessment of disability progression (Expanded Disability Status Scale), radiological measures, and no-evidence-of-disease-activity measures (clinical, radiological, and overall). Results were similar among patient groups stratified by level of disease activity. Safety outcomes were consistent with natalizumab's known safety profile. Data from country-specific observational studies and registries varying in size and scope support the effectiveness and safety of natalizumab in a broad range of patients in clinical practice. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0303-8467 1872-6968 |
| العلاقة: | boreal:177587; http://hdl.handle.net/2078.1/177587Test; info:pmid/27475049; urn:ISSN:0303-8467; urn:EISSN:1872-6968 |
| DOI: | 10.1016/j.clineuro.2016.07.001 |
| الإتاحة: | https://doi.org/10.1016/j.clineuro.2016.07.001Test http://hdl.handle.net/2078.1/177587Test |
| حقوق: | info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.3265AF44 |
| قاعدة البيانات: | BASE |
| تدمد: | 03038467 18726968 |
|---|---|
| DOI: | 10.1016/j.clineuro.2016.07.001 |